Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
The bottom half of the rankings included Reckitt’s Mucinex, Johnson & Johnson’s Tremfya, Novo Nordisk’s Wegovy, Haleon’s Advil and AstraZeneca’s Breztri Aerosphere. Advil had the lowest estimated ...
This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property ...
Associate Health Minister David Seymour has commended Pharmac’s progress in expanding access to essential medicines for New Zealanders, driven by the government’s historic $6.294 billion funding ...
Pharmac’s achievements as historic funding enable access to new, life-saving medicines for New Zealanders, Associate Health Minister David Seymour said. Pharmac, New Zealand's medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback